OUR PROGRAMS

OUR PROGRAMS

We are also leveraging our expertise to target other post-translational modification enzymes

Peripheral neuropathies, depression, and cardiac diseases

While our first program on selective HDAC6 inhibitors focuses on the neurodegenerative diseases ALS and AD, exciting emerging biology around HDAC6 suggests an application to other diseases, particularly peripheral neuropathies, depression, and cardiac diseases.

We are also leveraging our expertise to target other post-translational modification (PTM) enzymes.